PubMed

Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization.

Khan MA, Goila-Gaur R, Kao S, Miyagi E, Walker RC Jr, Strebel K.

Retrovirology. 2009 Nov 3;6:99.PMID: 19886996 [PubMed - in process]Related articlesFree article

Human cellular restriction factors that target HIV-1 replication.

Strebel K, Luban J, Jeang KT.

BMC Med. 2009 Sep 16;7:48. Review.PMID: 19758442 [PubMed - indexed for MEDLINE]Related articlesFree article

The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.

Andrew AJ, Miyagi E, Kao S, Strebel K.

Retrovirology. 2009 Sep 8;6:80.PMID: 19737401 [PubMed - indexed for MEDLINE]Related articlesFree article

Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.

Miyagi E, Andrew AJ, Kao S, Strebel K.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2868-73. Epub 2009 Feb 5.PMID: 19196977 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif.

Goila-Gaur R, Khan MA, Miyagi E, Strebel K.

J Virol. 2009 Jan;83(2):1156-60. Epub 2008 Nov 12.PMID: 19004939 [PubMed - indexed for MEDLINE]Related articlesFree article

Guidelines for naming nonprimate APOBEC3 genes and proteins.

LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jónsson SR, Landau NR, Löchelt M, Malik HS, Malim MH, Münk C, O'Brien SJ, Pathak VK, Strebel K, Wain-Hobson S, Yu XF, Yuhki N, Harris RS.

J Virol. 2009 Jan;83(2):494-7. Epub 2008 Nov 5. No abstract available. PMID: 18987154 [PubMed - indexed for MEDLINE]Related articlesFree article

Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1.

Watashi K, Khan M, Yedavalli VR, Yeung ML, Strebel K, Jeang KT.

J Virol. 2008 Oct;82(20):9928-36. Epub 2008 Aug 6.PMID: 18684817 [PubMed - indexed for MEDLINE]Related articlesFree article

APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages.

Miyagi E, Schwartzkopff F, Plishka R, Buckler-White A, Clouse KA, Strebel K.

Virology. 2008 Sep 30;379(2):266-74. Epub 2008 Aug 3.PMID: 18675436 [PubMed - indexed for MEDLINE]Related articlesFree article

APOBEC3G encapsidation into HIV-1 virions: which RNA is it?

Strebel K, Khan MA.

Retrovirology. 2008 Jul 2;5:55.PMID: 18597677 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV-1 Vif, APOBEC, and intrinsic immunity.

Goila-Gaur R, Strebel K.

Retrovirology. 2008 Jun 24;5:51. Review.PMID: 18577210 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation.

Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, Pitha PM.

Virology. 2008 Mar 30;373(1):85-97. Epub 2007 Dec 20.PMID: 18082865 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.

Goila-Gaur R, Khan MA, Miyagi E, Kao S, Opi S, Takeuchi H, Strebel K.

Virology. 2008 Mar 1;372(1):136-46. Epub 2007 Nov 19.PMID: 18023836 [PubMed - indexed for MEDLINE]Related articlesFree article

Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K.

J Virol. 2007 Dec;81(24):13346-53. Epub 2007 Oct 10.PMID: 17928335 [PubMed - indexed for MEDLINE]Related articlesFree article

Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.

Kao S, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Takeuchi H, Strebel K.

Virology. 2007 Dec 20;369(2):329-39. Epub 2007 Sep 6.PMID: 17825339 [PubMed - indexed for MEDLINE]Related articlesFree article

Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity.

Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K.

Retrovirology. 2007 Aug 29;4:61.PMID: 17727729 [PubMed - indexed for MEDLINE]Related articlesFree article

Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.

Khan MA, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, Kao S, Strebel K.

Retrovirology. 2007 Jul 16;4:48.PMID: 17631688 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV accessory genes Vif and Vpu.

Strebel K.

Adv Pharmacol. 2007;55:199-232. Review. No abstract available. PMID: 17586316 [PubMed - indexed for MEDLINE]Related articles

Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.

Takeuchi H, Buckler-White A, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Kao S, Sokolskaja E, Pertel T, Luban J, Strebel K.

J Virol. 2007 Aug;81(15):8080-90. Epub 2007 May 23.PMID: 17522232 [PubMed - indexed for MEDLINE]Related articlesFree article

Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.

Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K.

J Virol. 2007 Aug;81(15):8236-46. Epub 2007 May 23.PMID: 17522211 [PubMed - indexed for MEDLINE]Related articlesFree article

Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.

Iwatani Y, Takeuchi H, Strebel K, Levin JG.

J Virol. 2006 Jun;80(12):5992-6002.PMID: 16731938 [PubMed - indexed for MEDLINE]Related articlesFree article